Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. The company develops an yttrium-90 based precision radionuclide therapy device; RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing a universal laboratory cooling device; hydrogel; and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Precisiongel names. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Kennewick, Washington.
Metrics to compare | RDGL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRDGLPeersSector | |
---|---|---|---|---|
P/E Ratio | −17.8x | −10.1x | −0.5x | |
PEG Ratio | −1.48 | −0.15 | 0.00 | |
Price/Book | −9.2x | 8.2x | 2.6x | |
Price / LTM Sales | 1,128.1x | 3.3x | 3.3x | |
Upside (Analyst Target) | - | 82.7% | 45.1% | |
Fair Value Upside | Unlock | −3.8% | 7.4% | Unlock |